Zydus receives Orphan Drug Designation from US FDA for malaria treatment
The Orphan Drug Designation provides up to seven years of marketing exclusivity in the US
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Medicines for Malaria Venture
Zydus announces completion of Phase-I trials of ZY19489
ZY19489 has the potential to be a single-dose cure for P. falciparum and P. vivax malaria due to its novel mechanism of action,…
Ipca Laboratories in agreement with MMV
Jointly develop a novel antimalarial co-formulation named 'Atoguanil' Ipca Laboratories has entered into an agreement with…
Merck Serono and Medicines for Malaria Venture sign agreement
To develop potential antimalarial therapy